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Reneé de Waal*, Karen Cohen, Gary Maartens*
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Abstract
Background: Lipoatrophy and/or central fat gain are observed frequently in patients on antiretroviral therapy (ART). Both
are assumed to be antiretroviral adverse drug reactions.
Methods: We conducted a systematic review to determine whether fat loss or gain was more common in HIV-infected
patients on ART than in uninfected controls; was associated with specific antiretrovirals; and would reverse after switching
antiretrovirals.
Results: Twenty-seven studies met our inclusion criteria. One cohort study reported more lipoatrophy, less subcutaneous fat
gain, but no difference in central fat gain in HIV-infected patients on ART than in controls. Randomised controlled trials
(RCTs) showed more limb fat loss (or less fat gain) with the following regimens: stavudine (versus other nucleoside reverse
transcriptase inhibitors (NRTIs)); efavirenz (versus protease inhibitors (PIs)); and NRTI-containing (versus NRTI-sparing). RCTs
showed increased subcutaneous fat after switching to NRTI-sparing regimens or from stavudine/zidovudine to abacavir/
tenofovir. There were no significant between-group differences in trunk and/or visceral fat gain in RCTs of various regimens,
but results from efavirenz versus PI regimens were inconsistent. There was no significant between-group differences in
central fat gain in RCTs switched to NRTI-sparing regimens, or from PI-containing regimens.
Conclusions: There is clear evidence of a causal relationship between NRTIs (especially thymidine analogues) and
lipoatrophy, with concomitant PIs possibly having an ameliorating effect or efavirenz causing additive toxicity. By contrast,
central fat gain appears to be a consequence of treating HIV infection, because it is not different from controls, is not linked
to any antiretroviral class, and doesn’t improve on switching.
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Introduction
Fat redistribution, also called lipodystrophy, is frequently
observed in patients on long term antiretroviral therapy (ART)
[1]. Some patients develop subcutaneous fat loss, or lipoatrophy;
others gain fat, particularly in the breasts, dorsocervical fat pads,
and viscerally. Individuals with mixed phenotypes of fat loss and
fat gain also occur commonly. Fat redistribution is also associated
with metabolic abnormalities, notably dyslipidaemia and insulin
resistance, which increase the risk of cardiovascular disease [2].
Lipoatrophy has been associated with exposure to thymidine
analogue nucleoside reverse transcriptase inhibitors (NRTIs) [3].
Central fat gain is also assumed to be an adverse drug reaction [4].
However, there is evidence that visceral abdominal fat in HIV-
infected patients on ART is not increased relative to healthy
controls [5]. Untreated HIV infection eventually results in wasting,
including loss of adipose tissue. Fat gain, which is widely prevalent
in the general population and increases with age, may in part be
the result of effective ART reversing fat loss due to HIV infection.
It is important to determine whether lipodystrophy is an adverse
drug reaction to avoid unnecessary drug substitutions which may
result in risks of virologic failure, new toxicities, and undermining
patient confidence if the lipodystrophy does not improve.
Treatment adherence is compromised when patients believe they
have lipodystrophy from antiretrovirals [6].
If fat loss and fat gain were adverse antiretroviral drug reactions
they would occur more commonly in HIV-infected patients on
ART than in HIV-uninfected controls. Second, fat loss and/or fat
gain would be associated with specific antiretroviral drugs or drug
classes. Third, fat loss and/or fat gain would reverse after
switching the identified antiretroviral drugs. We conducted a
systematic review to test those three assumptions.
Methods
Eligibility criteria
Types of studies. To answer the question ‘Does fat loss and/
or fat gain occur more commonly in patients on ART than in
HIV-uninfected controls?’ we included prospective cohort studies
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comparing HIV-infected patients with ART exposure to popula-
tion controls either known or presumed to be HIV-uninfected. To
answer the questions ‘Is fat loss and/or fat gain associated with
specific antiretroviral drugs?’ we included randomised controlled
trials comparing antiretroviral regimens. To answer the question
‘Is fat loss and/or fat gain reversed after switching antiretroviral
drugs?’ we included studies where participants with virologic
suppression were randomised to continue their current ART
regimen or switch to an alternative regimen.
Participants. We included both ART-naı̈ve and ART-
experienced HIV-infected patients who were at least 12 years
old. For the cohort studies we included control participants who
were presumed to be HIV-uninfected. We excluded studies with
fewer than 20 participants in any arm.
Interventions. We included studies that used any antiretro-
viral regimens, given for at least 24 weeks, with the exception of
those containing hydroxyurea.
Outcome measures. We included studies with at least one
objective measure of fat distribution done at baseline, and
repeated at least once, at a minimum of 24 weeks after baseline.
Objective methods of measuring fat distribution included: dual-
energy x-ray absorptiometry (DEXA), computerized tomography
(CT), or magnetic resonance imaging (MRI). We included
measures done both as primary or secondary outcomes, and in
the whole study population, or within a sub-study. Specific
outcomes included:
To assess fat loss:
N Change from baseline in limb fat
N Change from baseline in subcutaneous adipose tissue (SAT)
N Proportion with $20% loss in limb fat
N Proportion with $20% loss in SAT
To assess fat gain:
N Change from baseline in trunk fat
N Change from baseline in visceral adipose tissue (VAT)
N Proportion with $20% gain in trunk fat
N Proportion with $20% gain in VAT.
Search strategies
We searched two electronic journal databases, PubMed and
EMBASE, for articles published between 1 January 1990 and 7
July 2011. We hand-searched electronic databases for the
Conferences on Retroviruses and Opportunistic Infections and
the International AIDS Society conferences, from 2001. There
was no language restriction, provided that an English translation
of the abstract was available. The PubMed search strategy terms
were as follows:
HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-
1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv
infect*[tw] OR human immunodeficiency virus[tw] OR human
immunedeficiency virus[tw] OR human immuno-deficiency vir-
us[tw] OR human immune-deficiency virus[tw] OR ((human
immun*) AND (deficiency virus[tw])) OR acquired immunodefi-
ciency syndrome[tw] OR acquired immunedeficiency syndro-
me[tw] OR acquired immuno-deficiency syndrome[tw] OR
acquired immune-deficiency syndrome[tw] OR ((acquired im-
mun*) AND (deficiency syndrome[tw])) OR ‘‘sexually transmitted
diseases, viral’’[MH:noexp]
AND
Figure 1. Flow diagram of study selection.
doi:10.1371/journal.pone.0063623.g001
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Search Antiretroviral Therapy, Highly Active[MeSH] OR
Anti-Retroviral Agents[MeSH] OR Antiviral Agents[MeSH:-
NoExp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR
((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND
(acquired immunodeficiency[tw])) OR ((anti) AND (acquired
immunedeficiency[tw])) OR ((anti) AND (acquired immuno-
deficiency[tw])) OR ((anti) AND (acquired immune-deficien-
cy[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw]))
OR
Search zalcitabine OR zidovudine OR lamivudine OR
stavudine OR didanosine OR tenofovir OR abacavir OR
emtricitabine OR nevirapine OR efavirenz OR delavirdine OR
etravirine OR rilpivirine OR amprenavir OR atazanavir OR
tipranavir OR indinavir OR saquinavir OR lopinavir OR
fosamprenavir OR ritonavir OR darunavir OR nelfinavir OR
enfurvirtide OR maraviroc OR raltegravir
AND
Search Lipodystrophy[mh] OR lipodystrophy[tiab] OR lypo-
dystrophy[tiab] OR lipodystrophies[tiab] OR lipohypertrophy[-
tiab] OR lipoatrophy[tiab] OR body fat distribution[mh] OR
fat[tiab] OR fats[tiab] OR abdominal fat[mh] OR adipose
tissue[mh] OR adipose [tiab] OR adiposity[tiab] OR temporal
wasting[tiab] OR buffalo hump[tiab].
Table 2. Change from baseline in limb fat (LF) on DEXA scan, and subcutaneous thigh fat (STF) and subcutaneous adipose tissue
(SAT) on CT scan: NRTI-containing regimens versus NRTI-sparing regimens.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[9] LFa LPVr+AZT+3TC 2703 g (22) 0.014 21930 g (5) .0.05
LPVr monotherapy 263 g (41) 2400 g (8)
[4] Percentage of body fat,
0 & 48 wks:c
LFa,b LPVr+ continue 2NRTIs 12.2; 13.4 (33d) NR ND NA
NVP+LPVr 11.1; 14.1 (33d) ND
[12] Mean (95% CI) g, 0 &
48 wks:f
Mean (95% CI) g,
96 wks:f
LFe AZT+3TC+LPVr 6360 (5919 to 6801); 6520




NVP+LPVr 6360 (5968 to 6752);
7030 (6618 to 7442) (26d)
7210
(6789 to 7631)
Mean (95% CI) cm2,
0 & 48 wks:f
Mean (95% CI)
cm2, 96 wks:f
SATe AZT+3TC+LPVr 118 (107 to 129); 126
(114 to 138) (22d)
NR 123 (111 to 135) NR
NVP+LPVr 118 (108 to 128);
132 (121 to 143) (26d)
142 (131 to 153)
[13] LFa EFV+3TC+(TDF or AZT or D4T) 8.9%g (188) NR 1.4% (171) ,0.001 vs NRTI-
sparing
LPVr+3TC+(TDF or AZT or D4T) 10.1%g (191) 9.8% (166) 0.013 vs NRTI-
sparing
EFV+LPVr (NRTI-sparing) 14.2%g (197) 17.6% (173)
[32] STFa ABC+continue other ARVs 18% (42) 0.57 ND NA
LPVr+NVP 17% (46) ND
SATa ABC+continue other ARVs 29% (43) 0.6 ND NA
LPVr+NVP 33% (47) ND
[18] LFe PIr+2NRTIs 0.37 kg (28) 0.253 vs NNRTI+PIr ND NA
NNRTI+2NRTIs 0.9 kg (21) 0.298h vs PIr+2NRTIs ND NA
NNRTI+PIr 0.79 kg (49) 0.793 vs NRTI+2NRTIs ND NA
[21] LFa EFV+2NRTIsi 2242 g (25) 0.086 2850 g (25)j 0.002
LPVr+EFV 562 g (22) 782 g (22)j
[11] LFa DRVr+ continue 2NRTIs 20.26% (74) ,0.001 ND NA
DRVr monotherapy 8.3% (67) ND NA
a. median; b. leg fat; c. absolute values at each time-point (change from baseline not reported); d. n at baseline (n at time-point not reported); e. mean; f. means
(corrected for differences in baseline values) and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from baseline not
reported); g. values derived from graph; h. calculated by authors of this review; i. DDI+3TC or DDI+AZT or AZT+3TC or D4T+ 3TC or DDI+D4T; j. at last visit (median
102 weeks).
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DRVr: ritonavir-boosted darunavir; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; NVP:
nevirapine; PIr: ritonavir-boosted PI; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t002
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Data collection
Two authors (RdW and KC) independently reviewed all study
abstracts identified by the search strategy, using a specially
designed eligibility form. We obtained the full articles, conference
abstracts or conference posters for all studies that met the inclusion
criteria. An independent translator reviewed articles that were
published in languages other than English. We resolved disagree-
ments as to study eligibility through consensus and discussion with
the third author (GM) if necessary. One author (RdW) extracted
data using a data extraction form; another author (KC) checked
the extracted data. Two authors (RdW and KC) assessed the risk
of bias of all included studies [7].
Results
We identified a total of 27 studies for inclusion in the review:
one cohort study comparing HIV-infected patients with controls
[8]; 18 randomised controlled trials comparing antiretroviral
regimens [3,4,9–24]; seven switching studies [25–31]; and one
study that fulfilled the criteria for both randomised controlled trials
and switching studies [32]. Our search of PubMed and Embase
Table 3. Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: PI versus NNRTI.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[3] LFa ATVr+(ABC+3TC or TDF+FTC) 25.2%b (105) NR 30.4% (94) 0.01
EFV+(ABC+3TC or TDF+FTC) 17.7%b (112) 16.5% (109)
[13] LFc LPVr+3TC+(TDF or AZT or D4T) 10.1%b (191) 9.8% (166) 0.007
EFV+3TC+(TDF or AZT or D4T) 8.9%b (188) NR 1.4% (171)
[18] LFa PIr+2NRTIs 0.37 kg (28) 0.30d ND NA
NNRTI+2NRTIs 0.9 kg (21) ND NA
[19] LFc LPVr+AZT+3TC or LPV monotherapye 11.8% (NR) NR 18.5%b (74) NR
EFV+AZT+3TC 3.1% (NR) NR 29%b (32)
[24] SATa ATV+AZT+3TC 12.8 cm2b (62). 95% CI for
difference: 216.8 to 27.5
NR ND NA
EFV+AZT+3TC 7.6 cm2b (47) ND NA
[20,33] LFc,f NFV+(AZT+3TC or DDI+D4T) 24.7%b (23) NR 223.7%b (11) NR
EFV+(AZT+3TC or DDI+D4T) 1.5%b (26) 9.9%b (16)
a. mean; b. values derived from graph; c. median; d. calculated by authors of this review; e. if virologically suppressed for 3 months; f. as-treated analysis.
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC:
emtricitabine; LPVr: ritonavir-boosted lopinavir; NFV: nelfinavir; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t003
Table 4. Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: NRTI versus NRTI.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[3] LFa ABC+3TC+(ATVr or EFV) 22.8%b (107) NR 24.9% (102) 0.46
TDF+FTC+(ATVr or EFV) 19.7%b (110) 20.9% (101)
[14] LFc ABC+3TC+continue PI or NNRTI 104 g (23) 0.92 ND NA
TDF+FTC+continue PI or NNRTI 75 g (24) ND NA
[22] LFa ABC+3TC+EFV 686 g (25) 0.001 913 g (25) ,0.001
D4T+3TC+EFV 21164 g (32) 21578 g (32)
[23] LFa ABC+continue other ARVs 483 g (44) 0.37 ND NA
TDF+continue other ARVs 329 g (49) ND NA
SATa ABC+continue other ARVs 8.0 cm2 (44) 0.96 ND NA
TDF+continue other ARVs 8.4 cm2 (49) ND NA
[20,33] LFc,d DDI+D4T+(EFV or NFV) 211.9%b (42) NR 226.4%b (22) NR
AZT+3TC+(EFV or NFV) 1.6%b (39) 1.7%b (24)
[16] LFa ABC+3TC+continue NNRTI or PI 0.3 kg (179e) 0.4 0.53 kg (NR) 0.46
TDF+FTC+continue NNRTI or PI 0.19 kg (178e) 0.42 kg (NR)
a. mean; b. values derived from graph; c. median; d. as-treated analysis; e. n at baseline (n at time-point not reported).
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC:
emtricitabine; NFV: nelfinavir; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t004
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databases identified 3031 potential abstracts. We identified a
further 67 articles through conference databases or other sources.
After removing duplicate records, we screened 3042 abstracts and
excluded 2966 as they did not meet our inclusion criteria. We
retrieved and assessed the full text articles for the remaining 76,
and excluded 49 that did not meet our inclusion criteria (see
Figure 1 and Table S1). We assessed two articles that were
published in Spanish through means of a translator. We included
the full text articles for five studies that we identified through
conference abstracts.
Characteristics of included studies
Fat distribution measures were done in all participants for 15
studies: one cohort study [8]; nine randomised controlled trials
comparing antiretroviral regimens [4,12,13,15,16,18,19,23,32];
and five switching studies [25,27,29–31]. They were done in a
subset of participants only in the remaining 12 studies [3,9–
11,14,17,21,22,24,26,28,33]. The characteristics of the included
Table 5. Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: PI versus PI.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[15] LFa ATVr+D4T+3TC 2% (72) NR 29% (55) .0.05
ATV+D4T+3TC 23% (89) 217% (67)
SATa ATVr+D4T+3TC 12% (68) NR 8% (56) .0.05
ATV+D4T+3TC 12% (85) 2% (62)
[17] LFb TPVr100+TDF+3TC 1.4% (46) 0.02 vs LPVr+TDF+3TC ND NA
TPVr200+TDF+3TC 1.6% (48) 0.14 vs LPVr+TDF+3TC ND NA
LPVr+TDF+3TC 2.8% (45) ND NA
SATb TPVr100+TDF+3TC 22.1 cm2 (46) 0.03 vs LPVr+TDF+3TC ND NA
TPVr200+TDF+3TC 4.2 cm2 (48) 0.13 vs LPVr+TDF+3TC ND NA
LPVr+TDF+3TC 17.6 cm2 (45) ND NA
a. mean; b. median.
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; D4T: stavudine; LPVr: ritonavir-boosted lopinavir; TDF: tenofovir; TPVr100: tipranavir/
ritonavir 500/100 mg twice a day; TPVr200: tipranavir/ritonavir 500/200 mg twice a day.
doi:10.1371/journal.pone.0063623.t005
Table 6. Change from baseline in limb fat (LF) on DEXA scan













18.1% (40) 0.95b 18.2% (37) 0.88b
EFV+TDF
+FTC
17.7% (46) 17.0% (38)
a. mean; b. p value calculated by authors of this review.
Antiretrovirals: EFV: efavirenz; FTC: emtricitabine; RAL: raltegravir; TDF:
tenofovir.
doi:10.1371/journal.pone.0063623.t006
Table 7. Proportion of patients with peripheral lipoatrophy on DEXA scan: NRTI-containing regimens versus NRTI-sparing
regimens.
Study Definition Arm Week 48 (n) p value
Week
96 (n) p value
[9] .20% loss of LF LPVr+AZT+3TC 27.3% (22) 0.018 ND NA
LPVr monotherapy 4.9% (41) ND
ORa LPVr+AZT+3TC vs LPVr
monotherapy 7.06. 95% CI 1.11
to 78.69
[13] $20% loss of LF EFV+3TC+(TDF or AZT or D4T) 21% (188) NR 32% (171) ,0.001 vs NRTI-sparing
LPVr+3TC+(TDF or AZT or D4T) 10% (191) 17% (166) 0.023 vs NRTI-sparing
EFV+LPVr (NRTI-sparing) 7% (197) 9% (173)
[11] .20% loss of LF DRVr+ continue 2NRTIs 10.8% (74) 0.035 ND NA
DRVr monotherapy 1.5% (67) ND NA
a. adjusted for age and sex.
LF: limb fat; NA: not applicable; ND: not done; NR: not reported; OR: odds ratio.
Antiretrovirals: 3TC: lamivudine; AZT: zidovudine; D4T: stavudine; DRVr: ritonavir-boosted darunavir; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t007
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studies are summarised in Table 1, and risk of bias assessment in
Table S2.
Participants
Twelve randomised controlled trials enrolled antiretroviral-
naı̈ve participants [3,9,10,12,13,15,17–19,22,24,33]. The cohort
study [8], seven randomised controlled trials
[4,11,14,16,21,23,32], and all the switching studies enrolled
antiretroviral-experienced participants. The cohort study enrolled
participants both with and without lipodystrophy. Two rando-
mised controlled trials enrolled only participants with clinical or
self-reported features of lipoatrophy [23,32]; and two enrolled
participants both with and without lipoatrophy [14,21]. Three
switching studies enrolled only participants with clinical or self-
reported lipoatrophy [29–31]; and one enrolled participants with
features of abdominal fat accumulation, defined as a waist-to-hip
ratio of .0.9, with a waist circumference .88.2 or .75.3 cm in
men and women respectively [25]. For the remaining studies it was
not reported whether or not participants had features of
lipodystrophy at baseline.
Table 8. Proportion of patients with peripheral lipoatrophy on DEXA scan: PI versus NNRTI.
Study Definition Arm Week 48 (n) p value Week 96 (n) p value
[13] $20% loss of LF LPVr+3TC+(TDF or AZT or D4T) 10% (191) NR 17% (166) 0.003
EFV+3TC+(TDF or AZT or D4T) 21% (188) 32% (171)
ORa EFV vs LPVr 2.63. 95% CI 1.49 to
4.64
,0.001
[19] .20% loss of LF LPVr+AZT+3TC or LPVr monotherapyb ND NA 5% (74) ,0.001
EFV+AZT+3TC ND 34% (32)
[33] .10% loss of LF NFV+(AZT+3TC or DDI+D4T) NR
EFV+(AZT+3TC or DDI+D4T) NR ND NA
ORc NFV vs EFV NR 0.06
a. adjusted for NRTI arm, race, sex, age, baseline extremity fat and baseline CD4 count; b. if virologically suppressed for 3 months; c. adjusted for NRTI assignment, age,
sex, race, and baseline BMI, HIV RNA and CD4 count.
LF: limb fat; NA: not applicable; ND: not done; NR: not reported; OR: odds ratio.
Antiretrovirals: 3TC: lamivudine; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; NFV: nelfinavir; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t008
Table 9. Proportion of patients with peripheral lipoatrophy on DEXA scan: NRTI versus NRTI.
Study Definition Arm Week 48 (n) p value
Week
96 (n) p value
[33] .10% loss of LF DDI+D4T+(EFV or NFV) NR
AZT+3TC+(EFV or NFV) NR ND NA
ORa DDI+D4T vs AZT+3TC 3.3.
95% CI 1.2 to 8.6
0.02
a. adjusted for age, sex, race, and baseline BMI, HIV RNA and CD4 count.
LF: limb fat; NA: not applicable; ND: not done; NR: not reported; OR: odds ratio.
Antiretrovirals: 3TC: lamivudine; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; NFV: nelfinavir.
doi:10.1371/journal.pone.0063623.t009
Table 10. Proportion of patients with peripheral lipoatrophy














21% (72) NR 29% (55) ,0.05
ATV+D4T
+3TC
30% (89) 49% (67)
LF: limb fat; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted
atazanavir; D4T: stavudine.
doi:10.1371/journal.pone.0063623.t010
Table 11. Proportion of patients with peripheral lipoatrophy


















a. p value calculated by the authors of this review.
LF: limb fat; NA: not applicable; ND: not done.
Antiretrovirals: EFV: efavirenz; FTC: emtricitabine; RAL: raltegravir; TDF:
tenofovir.
doi:10.1371/journal.pone.0063623.t011
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Interventions
All included studies involved a comparison of different
antiretroviral regimens, with the exception of the cohort study
that compared HIV-infected people with people who were known
or presumed to be HIV-uninfected [8]. Eight randomised
controlled trials [4,9,11–13,18,21,32], and two switching studies
[29,32] evaluated NRTI-sparing regimens; four randomised
controlled trials [3,19,24,33], and one switching study [31]
evaluated protease inhibitor (PI) versus non-nucleoside reverse
transcriptase inhibitor (NNRTI) regimens; six randomised con-
trolled trials [3,14,16,22,23,33], and five switching studies
[27,28,30,32,34] evaluated NRTI versus NRTI regimens; two
Table 12. Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: NRTI-containing
regimens versus NRTI-sparing regimens.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[9] TFa LPVr+AZT+3TC 2211 g (22) 0.665 346 g (5) .0.05
LPVr monotherapy 2579 g (41) 2859 g (8)
[4] Percentage of body fat,
0 & 48 wks:b
TFa LPVr+ continue 2NRTIs 20.6; 22.6 (33c) NR ND NA
NVP+LPVr 22.5; 24.0 (33c) ND
[12] Mean (95% CI) cm2,
0 & 48 wks:e
Mean (95% CI) cm2,
96 wks:e
VATd AZT+3TC+LPVr 100 (88 to 112); 104
(90 to 118) (22c)
NR 122 (108 to 135) NR
NVP+LPVr 100 (89 to 111); 109
(96 to 122) (26c)
111 (98 to 124)
[32] VATa ABC+continue other ARVs 215% (43) 0.1 ND NA
LPVr+NVP 24% (47) ND
[21] TFa EFV+2NRTIsf 133 gg (25) .0.05 2583 gg (25) .0.05
LPVr+EFV 2170 gg (22) 2206 gg (22)
[11] TFa DRVr+ continue 2NRTIs 5.9% (74) .0.05 ND NA
DRVr monotherapy 7.6% (67) ND
a. median; b. absolute values at each time-point (change from baseline not reported); c. n at baseline (n at time-point not stated); d. mean; e. means (corrected for
differences in baseline values) and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from baseline not reported); f.
DDI+3TC or DDI+AZT or AZT+3TC or D4T+3TC or DDI+D4T; g. values derived from graph.
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; DRVr: ritonavir-boosted darunavir; EFV: efavirenz; LPVr: ritonavir-
boosted lopinavir; NVP: nevirapine.
doi:10.1371/journal.pone.0063623.t012
Table 13. Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: PI versus NNRTI.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[3] TFa ATVr+(ABC+3TC or TDF+FTC) 26.1%b (105) NR 36.5% (94) 0.028
EFV+(ABC+3TC or TDF+FTC) 20.4%b (112) 21.1% (109)
VAT ATVr+(ABC+3TC or TDF+FTC) NR NA LR coefficientc
(ATVr vs EFV) 11.0 cm2
0.20
EFV+(ABC+3TC or TDF+FTC) NR 95% CI 25.9 to 27.9
[19] TFd LPVr+AZT+3TC or LPVre 6.9% (NR) NR 13.8%b (74) .0.05
EFV+AZT+3TC 15.2% (NR) 14.6%b (32)
[24] VATa ATV+AZT+3TC 15.3 cm2 (62). 95% CI for
difference: 210.4 to 12.6
NR ND NA
EFV+AZT+3TC 14.1 cm2 (46) ND
[20,33] TFd,f NFV+(AZT+3TC or DDI+D4T) 8.3%b (23) NR 26.8%b (11) NR
EFV+(AZT+3TC or DDI+D4T) 14.8%b (26) 32.6%b (16)
a. mean; b. values derived from graph; c. adjusted for treatment allocation, sex, age, race, and baseline HIV RNA, CD4 count and BMI; d. median; e. LPVr monotherapy if
virologically suppressed for 3 months; f. as treated analysis.
LR: linear regression; NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC: emtricitabine;
LPVr: ritonavir-boosted lopinavir; NFV: nelfinavir; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t013
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randomised controlled trials [15,17], and one switching study [25]
evaluated PI versus PI regimens; and one randomised controlled
trial [10], and one switching study [26] evaluated other
antiretroviral categories.
Outcomes
An objective measure of fat distribution was the primary study
endpoint in 15 studies [3,8,12,13,17,18,21,23–27,29,30,32]. In the
remaining studies, measures of fat distribution were secondary
endpoints.
HIV-infected patients compared with healthy
controls. The FRAM2 study compared fat distribution in
HIV-infected patients with healthy controls, using MRI at two
time-points separated by about five years [8]. The control
participants were recruited from the Visceral Fat and Metabolic
Rate in Young Adults sub-study of the Coronary Artery Risk
Development in Young Adults study. They were selected as they
had previous experience of fat distribution investigations, and had
a similar age and ethnic distribution to most HIV-infected patients
in the United States [35]. Although the analyses included HIV-
infected patients who had never been on ART (11.8% at baseline
and 5.7% at year 5), we included the study as only a small minority
were not on ART. Sub-group analyses by ART status were not
done.
There was clear evidence of fat loss in HIV-infected people,
53% of whom had lipoatrophy (defined as leg SAT below the 10th
percentile of controls) after five years of observation. Longer
duration of stavudine use was associated with less leg SAT. After
five years there was significantly less SAT at all sites in HIV-
infected men, but only in the limbs in HIV-infected women.
Multivariable analysis showed that increase in SAT over five years
was less in HIV-infected people at all sites except the lower trunk.
Table 14. Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: NRTI versus NRTI.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[3] TFa ABC+3TC+(ATVr or EFV) 24.9%b (107) NR 29.4%b (102) 0.76
TDF+FTC+(ATVr or EFV) 21.6%b (110) 27.3%b (101)
VAT ABC+3TC+(ATVr or EFV) ND NA LR coefficientc (ABC+3TC vs
TDF+FTC) 25.3 cm2
0.52
TDF+FTC+(ATVr or EFV) ND 95% CI 221.5 to 11.0
[22] TFa ABC+3TC+EFV ND NA 1225 g (25) 0.58
D4T+3TC+EFV ND 996 g (32)
[23] TFa Switch AZT/D4T to ABC+cont. other ARVs 618 g (44) 0.97 ND NA
Switch AZT/D4T to TDF+cont. other ARVs 607 g (49) ND
VATa Switch AZT/D4T to ABC+cont. other ARVs 2 cm2 (44) 0.49 ND NA
Switch AZT/D4T to TDF+cont. other ARVs 6.8 cm2 (49) ND
[20,33] TFd,e DDI+D4T+(EFV or NFV) 9.8%b (42) NR 20.7%b (22) NR
AZT+3TC+(EFV or NFV) 9.1%b (39) 13.6%b (24)
a. mean; b. values derived from graph; c. adjusted for treatment allocation, sex, age, race, and baseline HIV RNA, CD4 count and BMI; d. median; e. as treated analysis.
LR: linear regression; NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC: emtricitabine;
NFV: nelfinavir; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t014
Table 15. Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: PI versus PI.
Study Measure Arm Week 48 (n) p value Week 96 (n) p value
[15] TFa ATVr+D4T+3TC 12% (72) NR 16% (55) .0.05
ATV+D4T+3TC 15% (89) 14% (67)
VATa ATVr+D4T+3TC 28% (68) NR 33% (56) .0.05
ATV+D4T+3TC 34% (85) 32% (62)
[17] TFb TPVr100+TDF+3TC 20.8% (46) 0.005 vs LPVr+TDF+3TC ND NA
TPVr200+TDF+3TC 20.7% (48) 0.02 vs LPVr+TDF+3TC ND
LPVr+TDF+3TC 2.1% (45) ND
VATb TPVr100+TDF+3TC 26 cm2 (46) 0.4 vs LPVr+TDF+3TC ND NA
TPVr200+TDF+3TC 29 cm2 (48) 0.04 vs LPVr+TDF+3TC ND
LPVr+TDF+3TC 23 cm2 (45) ND
a. mean; b. median.
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; D4T: stavudine; LPVr: ritonavir-boosted lopinavir; TDF: tenofovir; TPVr100: tipranavir/
ritonavir 500/100 mg twice a day; TPVr200: tipranavir/ritonavir 500/200 mg twice a day.
doi:10.1371/journal.pone.0063623.t015
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By contrast, there was no evidence of regional fat accumulation
in HIV-infected people. After five years the amount of trunk SAT
and VAT was similar in HIV-infected and control women, while
HIV-infected men had less fat at all sites than control men. The
gains in VAT over five years were similar in HIV-infected people
and controls.
Fat loss: changes in limb fat and SAT with different
antiretroviral regimens. The changes from baseline in limb
fat and SAT are summarised in Tables 2, 3, 4, 5, and 6, and the
incidences of peripheral lipoatrophy (defined as $20% loss in limb
fat) are summarised in Tables 7, 8, 9, 10, and 11.
In general, participants who received NRTI-sparing regimens
gained more (or lost less) SAT or limb fat over time than those on
NRTI-containing regimens. However one study that compared an
abacavir-containing regimen with an NRTI-sparing regimen
found no significant between-arm differences in change in
subcutaneous thigh fat or SAT [32]. Participants who received
PI-containing regimens also gained more (or lost less) SAT or limb
fat over time than those on efavirenz-based regimens
[3,13,19,24,33]. The incidence of peripheral lipoatrophy (defined
as $20% loss of limb fat) was significantly lower in participants on
NRTI-sparing regimens compared with those on NRTI-contain-
ing regimens, and in those on PI-containing regimens compared
with those on EFV-based regimens [9,11,13,19].
There were no significant differences in average gains in SAT or
limb fat over time in the four studies that compared abacavir- with
tenofovir-based regimens [3,14,16,23]. One study found that
participants who received an abacavir-containing regimen gained
limb fat over time, in contrast to participants who received a
stavudine-containing regimen who lost limb fat over time (gain of
913 g versus loss of 1578 g, p,0.001) [22]. Another study found
that participants who received a zidovudine-lamivudine-contain-
ing regimen gained limb fat over time, in contrast to participants
who received a stavudine-didanosine-containing regimen who lost
limb fat over time (gain of 1.7% versus loss of 26.4%, p value not
reported) [33].
Unboosted atazanavir was associated with significant reduction
in limb fat at 96 weeks, while there was no significant change in
Table 16. Change from baseline in trunk fat (TF) on DEXA













18.9% (40) 0.63b 21.6% (37) 0.71b
EFV+TDF
+FTC
22.6% (46) 25.5% (38)
a. mean; b. p value calculated by authors of this review.
Antiretrovirals: EFV: efavirenz; FTC: emtricitabine; RAL: raltegravir; TDF:
tenofovir.
doi:10.1371/journal.pone.0063623.t016
Table 17. Switching studies: change from baseline in subcutaneous thigh fat (STF) and subcutaneous adipose tissue (SAT) on CT
scan: NRTI-containing regimens versus NRTI-sparing regimens.
Study Measure Arm Week 24 (n) p value Week 48 (n) p value Week 96 (n) p value
[32] STFa Cont AZT or D4T regimen 23% (24) NR ND NA ND NA
Switch to LPVr+NVP 8% (40) ND ND
[29] STFb Cont NRTI regimen ND NA 0 cm3 (35) 0.004 11 cm3 (25) 0.001
Switch to PI+NNRTI ND 42 cm3 (41) 120 cm3 (28)
SATb Cont NRTI regimen ND NA 1 cm3 (35) 0.004 14 cm3 (23) 0.088
Switch to PI+NNRTI ND 22 cm3 (39) 31 cm3 (30)
a. median; b. mean.
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: AZT: zidovudine; D4T: stavudine; LPVr: ritonavir-boosted lopinavir; NVP: nevirapine.
doi:10.1371/journal.pone.0063623.t017














[31] Mean (95% CI) 0
& 48 wks (kg):d
LF a,b Cont PI+
2NRTIs
ND NA NR (54c) 1.5 (1.3 to 1.8);




ND NR (52c) 1.2 (1.1 to
1.4); 1.2 (1.1 to 1.4)
ND
a. mean; b. leg fat; c. n at baseline (n at time-point not stated); d. means and 95% confidence intervals (calculated by the authors of this review) at each time-point
(change from baseline not reported).
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: D4T: stavudine; DDI: didanosine; NVP: nevirapine.
doi:10.1371/journal.pone.0063623.t018
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Table 19. Switching studies: change from baseline in limb fat (LF) on DEXA scan, and subcutaneous thigh fat (STF) and
subcutaneous adipose tissue (SAT) on CT scan: NRTI versus NRTI.
Study Measure Arm Week 24 (n) p value Week 48 (n) p value Week 96 p value
[28] LFa Cont AZT+3TC+EFV ND NA 2187 g (36). 95% CI for
difference: 57 to 837 g
0.024 ND NA
Switch TDF+FTC+EFV ND 261 g (38) ND
[32] STFb Cont AZT or D4T regimen 23% (24) NR ND NA ND NA
Switch AZT/D4T to ABC 0% (37) ND ND
[30] LFa Cont AZT or D4T regimen 0.08 kg (56) 0.02 ND NA ND NA
Switch AZT/D4T to ABC 0.39 kg (50) ND ND
STFa,c Cont AZT or D4T regimen 21.2 cm2 (56) 0.01 ND NA ND NA
Switch AZT/D4T to ABC 3.3 cm2 (50) ND ND
SATa Cont AZT or D4T regimen 21.2 cm2 (56) 0.001 ND NA ND NA
Switch AZT/D4T to ABC 13.9 cm2 (50) ND ND
[27] SATb Cont AZT+3TC 22.7%d(NR) NR 22.7%d (59) 0.03 ND NA
Switch to TDF+FTC 2.1%d (NR) 1.6%d (66) ND
LFb Cont AZT+3TC 3.2%d (NR) NR 1.1%d (59) 0.5 ND NA
Switch to TDF+FTC 3.9%d (NR) 5.2%d (66) ND
a. mean; b. median; c. right thigh; d. values derived from graph.
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; EFV: efavirenz; FTC: emtricitabine; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t019
Table 20. Switching studies: change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT














[25] LFa Continue PIr
+2NRTIs
ND NA 23.6% (54) 0.15 26.1% (54) 0.17
Switch PIr
to ATVr
ND 0.9% (112) 20.8% (112)
SATa Continue PIr
+2NRTIs
ND NA 25.9% (59) 0.16 29.7% (59) 0.6
Switch PIr
to ATVr
ND 22.1% (108) 23.5% (108)
a. mean.
NA: not applicable; ND: not done.
Antiretrovirals: ATVr: ritonavir-boosted atazanavir; PIr: ritonavir-boosted PI.
doi:10.1371/journal.pone.0063623.t020
Table 21. Switching studies: change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT














[26] LFa Cont PI
regimen
ND NA 171 g (35) 0.791 ND NA
Switch PI
to RAL
ND 32 g (39) ND
SATa Cont PI
regimen
ND NA 3.6% (35) 0.496 ND NA
Switch PI
to RAL
ND 21.9% (39) ND
a. median.
NA: not applicable; ND: not done; RAL: raltegravir.
doi:10.1371/journal.pone.0063623.t021
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limb fat in the ritonavir-boosted atazanavir arm (both arms were
on stavudine and lamivudine) [15]. The proportion of participants
with $20% loss in limb fat was significantly greater in the
unboosted atazanavir arm at 96 weeks [15]. However, there were
no significant between-group differences in absolute change from
baseline in SAT or limb fat with ritonavir-boosted versus
unboosted atazanavir [15]. There were no significant between-
group differences in absolute change from baseline in SAT or limb
fat in a study comparing ritonavir-boosted tipranavir (at the
registered dose) with ritonavir-boosted lopinavir [17].
In the one study that compared raltegravir with efavirenz,
average gains in limb fat over time and the incidence of
lipoatrophy were similar in both groups [10].
Fat gain: changes in trunk fat or VAT with different
antiretroviral regimens. In general, participants randomised
to different ART regimens gained similar amounts of trunk fat or
VAT over time. The changes from baseline in trunk fat and VAT
are summarised in Tables 12, 13, 14, 15, 16.
There were no significant between-group differences in changes
from baseline in trunk fat or VAT in the six studies that compared
NRTI-sparing and NRTI-containing regimens [4,9,11,12,21,32],
and in the four studies that compared different NRTI-containing
regimens [3,22,23,33]. Similarly, there were no significant
differences in the incidences of lipohypertrophy (defined as
.20% gain in trunk fat) [9,11,19].
The results of studies that compared PIs and NNRTIs were not
consistent. One study found that participants who received
ritonavir-boosted atazanavir had significantly greater increases in
trunk fat at week 96 than those who received efavirenz (36.5%
versus 21.1% respectively, p = 0.028) [3]. Another study found no
significant changes at week 48 in VAT between those who
received unboosted atazanavir compared with those who received
efavirenz (15.3 cm2 versus 14.1 cm2 respectively, 95% confidence
interval for the difference: 210.4 to 12.6 cm2) [24]. There were no
significant between-group differences in changes from baseline in
trunk fat, or in incidence of lipohypertrophy in one study that
compared ritonavir-boosted lopinavir and efavirenz [19]. One
study found that participants who received efavirenz gained more
trunk fat over time on average than those who received nelfinavir,
however it was not reported whether or not the difference was
statistically significant [33].
There were no significant between-group changes from baseline
in trunk fat or VAT in those who received ritonavir-boosted
atazanavir compared with unboosted atazanavir in one study [15].
A study that compared ritonavir-boosted tipranavir and ritonavir-
boosted lopinavir found small, but statistically significant between-
group differences in changes from baseline in both trunk fat and
VAT: those who received ritonavir-boosted tipranavir lost trunk
fat over time, while those who received ritonavir-boosted lopinavir
gained trunk fat over time [17].
In the one study that compared raltegravir with efavirenz, gains
in trunk fat over time were similar in both groups [10].
Changes in limb fat and SAT after switching
antiretroviral regimens. In general, participants who were
switched away from NRTI-containing, or more specifically
thymidine analogue-containing, regimens gained limb fat over
time, when compared with participants who continued NRTI- or
thymidine analogue-containing regimens, who generally lost limb
fat [27–30,32,34].
There were no significant between-group differences in changes
from baseline in limb fat or SAT in studies that switched to
NNRTI- from PI-containing regimens [31], to ritonavir-boosted
atazanavir from other ritonavir-boosted PI regimens [25], or to
raltegravir from PI regimens [26].















[29] VATa Cont NRTI
regimen
ND NA 5 cm3 (35) 0.987 17 cm3 (23) 0.566
Switch to
PI+NNRTI
ND 7 cm3 (39) 6 cm3 (30)
a. mean.
NA: not applicable; ND: not done.
doi:10.1371/journal.pone.0063623.t022














[31] Mean (95% CI) 0
& 48 wks (kg):c
TF a Cont PI+
2NRTIs
ND NA NR (54b) 7.8 (6.9 to 8.7);




ND NR (52b) 6.3 (5.7 to 6.9);
5.9 (5.2 to 6.7)
ND
a. mean; b. n at baseline (n at time-point not stated); c. means and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from
baseline not reported).
NA: not applicable; ND: not done; NR: not reported.
Antiretrovirals: D4T: stavudine; DDI: didanosine; NVP: nevirapine.
doi:10.1371/journal.pone.0063623.t023
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Changes from baseline in limb fat, subcutaneous thigh fat and
SAT are summarized in Tables 17, 18, 19, 20, and 21.
Changes in trunk fat or VAT after switching antiretroviral
regimens. In general, participants who were switched away
from NRTI-containing regimens, or from thymidine analogue-
containing regimens, had similar increases in trunk fat over time to
those who continued NRTI- or thymidine analogue-containing
regimens [29,30].
There were no significant between-group differences in changes
from baseline in trunk fat or VAT in studies that switched to
NNRTI- from PI-containing regimens [31], to ritonavir-boosted
atazanavir from other ritonavir-boosted PI regimens [25], or to
raltegravir from PI regimens [26].
Changes from baseline in trunk fat and VAT are summarised in
Tables 22, 23, 24, 25, and 26.
Discussion
We found overwhelming evidence that lipoatrophy is an
antiretroviral adverse drug reaction. Subcutaneous fat volumes
are considerably lower in patients on ART than in controls,
subcutaneous fat loss progresses on ART, is associated with
stavudine and zidovudine use, and partially reverses after
switching to abacavir, tenofovir or an NRTI-sparing regimen.
By contrast, central fat gain does not appear to be an antiretroviral
adverse drug reaction. Visceral and trunk fat volume is no different
in women on ART compared with control women, and is less in
men on ART than in control men. Visceral fat accumulates at the
same rate in patients on ART and controls. Finally, central fat gain
generally occurs at similar rates in HIV-infected patients
randomised to different ART regimens, is not associated with
any specific antiretroviral drug or drug class, and does not reverse
on switching antiretrovirals. We believe that this evidence
indicates that central fat gain is a consequence of treating HIV
infection, which normalizes the concentrations of inflammatory
markers such as TNF-a (tumour necrosis factor alpha) that are
known to cause wasting [36]. Lipoatrophy occurring together with
central fat gain results in an unusual appearance, which may have
persuaded clinicians that the fat gain is an antiretroviral adverse
drug reaction. The fact that diet and exercise have been shown to
improve central fat gain in patients on antiretroviral therapy















[28] TFa Cont AZT+
3TC+EFV
ND NA 358 g .0.05 ND NA
Switch TDF+
FTC+EFV
ND 130 g ND





















NA: not applicable; ND: not done.
Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; TDF: tenofovir.
doi:10.1371/journal.pone.0063623.t024















[25] TFa Continue PIr
+2NRTIs
ND NA 21.8% (57) 0.14 23.6% (57) 0.14
Switch PIr
to ATVr
ND 2.6% (112) 1.6% (112)
VATa Continue PIr
+2NRTIs
ND NA 20.5% (59) 0.27 1.6% (59) 0.68
Switch PIr
to ATVr
ND 4.6% (108) 3.4% (108)
a. mean.
NA: not applicable; ND: not done.
Antiretrovirals: ATVr: ritonavir-boosted atazanavir; PIr: ritonavir-boosted PI.
doi:10.1371/journal.pone.0063623.t025
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provides some support for our conclusion that it is a consequence
of lifestyle [37–39].
Efavirenz is associated with a higher risk of limb fat loss than PIs
when combined with NRTIs that cause fat loss. A possible
explanation for this observation is that the anti-apoptotic
properties of PIs partially ameliorate the loss of adipocytes by
increased apoptosis that is induced by NRTIs [40]. The
observation that unboosted atazanavir, which is a non-peptido-
mimetic PI that does not have anti-apoptotic properties, is
associated with more limb fat loss than ritonavir (a peptidomimetic
PI)-boosted atazanavir supports this hypothesis. Alternatively,
efavirenz may increase the adipocyte toxicity of thymidine
analogue NRTIs. Efavirenz has been shown to be more toxic to
adipocytes and to release more inflammatory cytokines than
lopinavir-ritonavir [41]. Furthermore, efavirenz also displays
mitochondrial toxicity in hepatocytes [42]; although we could
find no data to support this, it is possible that it has a similar effect
on adipocytes. Mitochondrial toxicity is thought to be a key
mechanism of thymidine analogue-induced lipoatrophy [3].
Our study has several limitations. First, many of the studies that
reported objective measures of fat redistribution by ART regimen
were convenience sub-studies of randomised controlled trials,
therefore patients undergoing DEXA and/or CT scans were not
randomised. However, fat distribution sub-studies generally
reported that the characteristics of the patients undergoing
imaging of fat tissue were not different from the parent trial
population. Many RCTs were powered according to efficacy end-
points, and not for objective measures of fat distribution. Second,
many studies reported only summary statistics and different
outcome measures were reported, which prevented us from
pooling data from different studies. Third, some studies did not
report statistical analyses of changes in body fat distribution by
study arm. Fourth, we were unable to assess the role of older
protease inhibitors (other than nelfinavir) or nevirapine in fat
redistribution as no studies with those antiretrovirals fulfilled our
inclusion criteria. Fifth, we found only one study that compared fat
changes over time in patients on ART and HIV-infected controls
that was conducted in the United States. This limits our ability to
generalise findings to other populations. Finally, we cannot
exclude the causative role of specific antiretrovirals in focal forms
of fat gain, such as buffalo humps, as the included studies reported
trunk or visceral fat changes only.
In conclusion, our systematic review supports the hypothesis
that peripheral lipoatrophy, but not central fat gain, is an
antiretroviral adverse drug reaction. Lipoatrophy can be avoided
and at least partially reversed by avoiding thymidine analogue
nucleoside reverse transcriptase inhibitors. Central fat gain
appears to be a consequence of treating HIV-infection, and
reflects patterns of fat gain seen in the HIV-uninfected population.
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